Welcome to the German Singaporean Network for Rheumatology Research (DeSiNet)
Rheumatologic disorders occur in all populations of the world. Disparities in frequency and severity between different ethnic groups have become of increasing interest and importance in the post-genomic era when searching for genetic markers and etiological pathomechanisms. In a similar way pharmacogenetic characteristics are relevant for population specific therapeutic studies in a global market of pharmaceutical products. This network aims to explore differences between European and Asian Pacific populations in the pathogenesis of rheumatic diseases, with the long-term goal of optimizing treatments according to ethnicity and genetic background of affected individuals.
Rheumatoid arthritis (RA) is the most frequent rheumatological disorder with similar frequency in many different populations of the world. In contrast, systemic lupus erythematosus (SLE) is very different in the Asian compared to the European population with a much higher frequency and worse prognosis in Asia. In recent years, genotyping and large scale transcription profiling have been performed by the partners in Berlin and Dresden. Molecular data networks and new biomarker candidates for extensive testing in different populations were established, including biomarkers that may predict response to new targeted therapies. Furthermore, standards for biobanking, cell sorting, clinical data storage and bioinformatic analysis with new algorithms for diagnostic classification were established.
Project and Objectives
The DeSi-Net Rheuma aims to establish a collaborative network with a bureau and workshops for scientific exchange. Standardized measures for data and sample acquisition will be defined. Comparative molecular analyses between European and Asian patients with RA and SLE will be performed. Other diseases may follow. The DeSiNet Rheuma is open for the participation of further partners from Europe and the APRA.